TABLE 1.
Baseline Characteristics of Patients in and not in Analytic Sample
| Covariate | Not in sample (n = 235) | In sample (n = 1373) | Test |
|---|---|---|---|
| Age, mean (SD) [range] | 57.5 (11.7) [22.3–86.2] | 57.6 (11.3) [23.5–85.4] | t(1606) = 0.18, p = .860 |
| Sex, n (%) | |||
| Male | 149 (63.4) | 939 (68.4) | |
| Female | 86 (36.6) | 434 (31.6) | χ2(1) = 2.3, p = .131 |
| Race/ethnicity, n (%) | |||
| Hispanic | 12 (5.1) | 73 (5.3) | |
| Non‐Hispanic Black | 12 (5.1) | 67 (4.9) | |
| Non‐Hispanic White | 190 (80.9) | 1165 (84.9) | |
| Non‐Hispanic Other/unknown | 21 (8.9) | 68 (4.9) | χ2(3) = 6.2, p = .104 |
| Body mass index, n (%) | |||
| <18.5 underweight | 8 (3.4) | 17 (1.2) | |
| 18.5–<25.0 normal | 94 (40.0) | 358 (26.1) | |
| 25.0–<30.0 overweight | 65 (27.7) | 499 (36.3) | |
| ≥30.0 obese | 68 (28.9) | 499 (36.3) | χ 2(3) = 27.3, p < .001 |
| Clinical stage, n (%) | |||
| II | 138 (58.7) | 815 (59.4) | |
| III | 97 (41.3) | 557 (40.6) | χ 2(1) = 0.04, p = .848 |
| Karnofsky Performance Status (KPS)a, n (%) | |||
| Fully active (90–100) | 184 (79.3) | 1162 (84.6) | |
| Restricted/ambulatory (50–80) | 51 (21.7) | 211 (15.4) | χ 2(1) = 5.9, p = .015 |
| Intent to save sphincter, n (%) | |||
| No | 65 (27.7) | 357 (26.0) | |
| Yes | 170 (72.3) | 1016 (74.0) | χ 2(1) = 0.29, p = .593 |
| Treatment, n (%) | |||
| 5‐FU | 83 (35.3) | 394 (28.7) | |
| 5‐FU + OXA | 43 (18.3) | 286 (20.8) | |
| CAPE | 65 (27.7) | 407 (29.6) | |
| CAPE+OXA | 44 (18.7) | 286 (20.8) | χ 2(3) = 4.3, p = .231 |
Note: Covariates reported as n (%).
Abbreviations: 5‐FU, 5‐fluorouracil; CAPE, capecitabine; OXA, oxaliplatin.
a
(KPS 90–100) fully active, able to carry on all predisease performance without restriction; (KPS 70–80) restricted in physically strenuous activity but ambulatory; and (KPS 50–60) ambulatory and capable of all self‐care but unable to perform any work activities.